Open AccessEpigenetic aging as a biomarker of dementia and related outcomes: a systematic review
Author(s) -
Aoshuang Zhou,
Zimu Wu,
Aung Zaw Zaw Phyo,
Daniel Torres,
Swarna Vishwanath,
Joanne Ryan
Publication year - 2022
Publication title -
epigenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.265
H-Index - 60
eISSN - 1750-192X
pISSN - 1750-1911
DOI - 10.2217/epi-2022-0209
Subject(s) - dementia , epigenetics , biomarker , cognitive aging , cognition , systematic review , meta analysis , cognitive decline , bioinformatics , medicine , clinical psychology , gerontology , biology , medline , disease , psychiatry , genetics , biochemistry , gene
Background: Biological aging may be a robust biomarker of dementia or cognitive performance. This systematic review synthesized the evidence for an association between epigenetic aging and dementia, mild cognitive impairment and cognitive function. Methods: A systematic search was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: 30 eligible articles were included. There was no strong evidence that accelerated epigenetic aging was associated with dementia/mild cognitive impairment (n = 7). There was some evidence of an association with poorer cognition (n = 20), particularly with GrimAge acceleration, but this was inconsistent and varied across cognitive domains. A meta-analysis was not performed due to high study heterogeneity. Conclusion: There is insufficient evidence to indicate that current epigenetic aging clocks can be clinically useful biomarkers of dementia or cognitive aging.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom